Please use this identifier to cite or link to this item:
|Title:||MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212||Authors:||La Rosa, V
Ortiz Canseco, J
Pasca M., R
Raju R., M
Porretta G., C
Ioerger T., R
Sacchettini J., C
De Logu, A
Rubin E., J
De Rossi, E.
|Issue Date:||2012||Project:||None||Journal:||ANTIMICROBIAL AGENTS AND CHEMOTHERAPY||Abstract:||
The 1,5-diarylpyrrole derivative BM212 was previously shown to be active against multidrug-resistant clinical isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria. To determine its mechanism of action, we identified the cellular target. Spontaneous Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated. By the screening of genomic libraries and by whole-genome sequencing, we found that all the characterized mutants showed mutations in the mmpL3 gene, allowing us to conclude that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (mycobacterialmembrane protein, large) family. Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m-chlorophenylhydrazone, and verapamil. Uptake/efflux experiments with [ 14C]BM212 demonstrated that resistance is not driven by the efflux of BM212. Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.
|Appears in Collections:||Publications|
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.